Second, renin-angiotensin system inhibitors (RASi) and sodium glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce risk of CKD progression irrespective of primary kidney diagnosis [10–16]. This evidence concerns the gene MMP19 and chronic kidney disease.